Over a one-year follow-up period, the QoL remained stable, while the societal costs decreased in both G+/P- individuals and HCM patients, and a significant reduction in BoD was observed among symptomatic oHCM patients, in particular those classified as NYHA III.
R. Mangal, S. Schoonvelde, I. Wiethoff et al.· European Heart Journal· 0 citations
Clinical cohort findings that rare monoallelic LoF variants in ZNF536 underlie a genetic neurodevelopmental disorder characterized by developmental delay, autism, and behavioral dysregulation support a role for ZNF536 as a dosage-sensitive regulator of cortical development.
S. Hiatt, Wen-Jing Zhao, Zhong-Qing Wang et al.· American Journal of Human Ge...· 0 citations
A case series of an additional 13 affected individuals with RNF13 variants (2 missense, 11 truncating) supports and broadens previous reports and helps to define a narrow but critical region of the protein that is intolerant to truncating variation, although the gene is not highly constrained.
D. Latner, S. Hiatt, C. Finnila et al.· American Journal of Medical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.